about
Structural integrity versus radiographic progression in rheumatoid arthritisTwelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to dateThe role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry.Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.[Polyarthritis flare in patient with ankylosing spondylitis treated with infliximab].Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting.Clinical and serological features of juvenile systemic lupus erythematosus in an italian tertiary centre of pediatric rheumatology.Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives.Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study.Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.Sonographic findings in a case of cactus thorn arthritis.Interreader reliability in assessment of nailfold capillary abnormalities by beginners: pilot study of an intensive videocapillaroscopy training program.The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian expertsThe Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and FutureSarilumab: patient-reported outcomes in rheumatoid arthritisSAT0214 Reliability and Validity of the Italian Version of the Ucla-Scleroderma Clinical Trial Consortium-Gastrointestinal Tract Instrument in Patients with Systemic SclerosisTocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection[The ultrasound assessment of the psoriatic arthritis: from joint to skin]Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registryComment on: Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study: replyBone erosions in rheumatoid arthritis: ultrasound findings in the early stage of the diseaseThe 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical SettingMavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritisPisotriquetral arthritis: 'forgotten' joint in ultrasound imaging of the wrist
P50
Q26777897-918977CD-1DA1-4429-A2A0-CCADE549BA65Q31021097-621B1A77-393B-4F03-B7EE-4F665D87838FQ33881234-0B70563D-EC7F-4BC2-95E5-155D44F1A3E8Q38745066-99ADF51E-005A-4A1D-93D9-BF8C37D3F570Q38988087-73308523-0A91-49FA-9036-B0434281E371Q39341401-6153AC60-3BB2-4A42-98BE-0046D1C75028Q40179378-8942C2A6-D3A4-435A-A639-A6D39393E210Q40344312-79D65BF3-49CF-44C8-9607-A7EFF1F79D71Q40556448-CA4F1302-1BE7-4C83-99B5-5A19A0C654F6Q40573992-97DD24ED-848A-4919-89E8-8FCD4BADADF6Q46531899-AD9D49EA-F18B-47B3-AB20-6CDA8326B86CQ46973774-362B5C54-9AC8-4708-9355-E943A87A0947Q47693399-87CBB833-ECB3-4BC5-BFFE-09CED56B7AD2Q47781956-391CF783-CA5A-480C-910E-F3A3D2DCB8E0Q48037957-096C9933-B5F1-4F5A-A548-A122AC85DE5FQ48112019-1D0905A5-E554-4BA7-9CE1-7BD83DC1CD3BQ48274745-F8017DD2-EF78-4008-90CD-C86699C0E7ACQ48534268-3A81DA4C-0987-40F1-9F2F-63D48C6CBF65Q54998113-A9B205BB-DA72-4302-B29A-4B5C04E8D21DQ58551015-C545A042-DBB4-4AFA-BF7E-526828B98D1EQ58567074-CE6CBE74-A4D2-4B11-A615-4DB9F0FD8F81Q58735831-EDFF0934-94A9-4E73-9898-B2573C515F57Q60263171-F2165850-7588-4B76-B9FD-20C87AF0985CQ60300744-972A6462-8906-48C0-A63E-EB706F4FC13DQ82836420-76F992E6-E1E5-4202-BC05-168397F2651CQ85749840-55E5D2B4-C5AF-46C1-99EA-BFAD647A6C97Q86069755-E0B60A57-D1F3-4191-A943-F89EB1808920Q87241743-9EA091F4-1E24-4AE1-B1E5-365AB9CF7FA3Q88891501-7CEE3DEC-1B02-4B13-93A1-C009575817C5Q92818168-A47E75E5-2966-42AB-9D21-BA4FFF4A941CQ96229313-02FAE6CA-4C6A-479B-9254-1B67D6F76A1D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrea Becciolini
@ast
Andrea Becciolini
@en
Andrea Becciolini
@es
Andrea Becciolini
@nl
type
label
Andrea Becciolini
@ast
Andrea Becciolini
@en
Andrea Becciolini
@es
Andrea Becciolini
@nl
prefLabel
Andrea Becciolini
@ast
Andrea Becciolini
@en
Andrea Becciolini
@es
Andrea Becciolini
@nl
P106
P1153
36454683900
P31
P496
0000-0002-1051-8511